SSRI CHINA news

SSRI CHINA and its headquarter Social Survey Research Information Co., Ltd. (SSRI) have recently completed a syndicated market research study on China’s COPD Market. This report provides extensive information from secondary research and primary research based on 200 COPD treaters, covering a range of topics from current diagnosis and treatment, current prescription and satisfaction, and future outlook on the market.

• Increasing number of patients, with physicians and the government authorities citing air pollution as a cause
• The most commonly used product for COPD is ICS/LABA with 73% usage
• Within the 17 pipeline products, awareness of Boehringer Ingelheim's olodaterol (Striverdi) is the highest with 52%
• GSK has the highest sales rep visitation rate with 51%

For more details; click here (PDF file)